A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

Trial Details

NCT ID

NCT05543330

Phase

PHASE1 / PHASE2

Sponsor

Wuhan YZY Biopharma Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• M701 pleural infusion
• Pleural drainage
• Cisplatin pleural infusion

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Aged \>18 years and ≤ 75 years, male or female.
• Histologically or cytologically confirmed advanced non-small cell lung cancer that has progressed after at least one line of systemic anti-tumor tr…
• Malignant pleural effusion requiring intrathoracic perfusion treatment (malignant pleural effusion should be diagnosed histologically or cytologica…
• If the subject received latest systemic treatment regimen at least 1 course (at least 21 days for targeted therapy) and poorly controlled pleural e…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.